Gufic Biosciences Limited has submitted the Exchange a copy of Scrutinizers report of Annual General Meeting held on September 29, 2025. Further, the company has informed the Exchange regarding voting results.
GUFICBIO · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Gufic Biosciences submitted the voting results and scrutinizer's report for its 41st AGM held on September 29, 2025 via video conferencing. Seven ordinary resolutions were put to vote, including adoption of FY25 audited financial statements, declaration of a 10% final dividend (Re. 0.10 per share of face value Re. 1), re-appointment of Chairman & MD Jayesh P. Choksi (retiring by rotation), re-appointment of statutory auditors M/s. Mittal Agarwal & Co., ratification of cost auditor remuneration for FY25 and FY26, and appointment of M/s. Manish Ghia & Associates as secretarial auditor. Out of 31,982 shareholders on the record date (September 22, 2025), roughly 81.72% of outstanding equity (about 8.19 crore shares) participated in voting through remote e-voting and e-voting during the AGM. All seven resolutions were passed with over 99.99% votes in favour, with virtually no dissent — the highest dissent (about 2,813 votes against, 0.0034%) was on the re-appointment of Mr. Choksi.
Routine procedural filing — shareholders have approved all agenda items, confirming continuity of management and auditors, and a small final dividend of Re. 0.10 per share for FY25. No material surprise for the stock; expect the dividend to be paid as per the company's announced record and payment dates.